NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · USD

$1.39

+0.11 (+8.6%)· Recorded snapshot

Market cap	2.6M
Net income (ttm)	-11.1M
EPS (ttm)	-$8.73
Shares out	1.8M
Volume	17,278
Beta	1.64

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -11.1M
EPS (ttm): -$8.73
Market cap: 2.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-2,175

P25 n/aP50 n/aP75 n/a

ROIC-1,094.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NRSN indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001875091
Company name	NeuroSense Therapeutics Ltd.
Country	Israel
Country code	US
Earnings date	2026-09-25
Earnings time	bmo
Employees	17
Employees change	-1
Employees growth	-5.56%
Enterprise value	$2.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2025-12-31
First seen	2026-05-09
Fiscal year end	December
Founded	2017
Industry	Biotechnology
IPO date	2021-12-09
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0011809592
Last 10-K release date	2026-03-31
Last earnings date	2026-09-25
Last refreshed	2026-11-04
Last stock split date	2026-09-14
Last stock split type	Reverse
Market cap	$2.6M
Market cap category	Nano-Cap
Next earnings date	2027-03-30
Options	No
Price	$1.39
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-04
Symbol	NRSN
Website	https://www.neurosense-tx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-628.19%
FCF / EV yield	-323.97%
FCF yield	-324.52%
Forward EV/Sales	4.61x
Forward P/S	4.6x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-654,412
ROA	-247.3%
ROA (5Y)	-128.88%
ROCE	744.96%
ROE	-2,174.98%
ROE (5Y)	-1,071.18%
ROIC	-1,094.49%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-8,000
Depreciation and amortization	$16,000
EBIT	$-11.1M
EBITDA	$-11.1M
EPS	$-8.73
FCF per share	$-4.15
Financing cash flow	$4.4M
Free cash flow	$-7.7M
Free cash flow minus SBC	$-9.8M
Investing cash flow	$-8,000
Net cash flow	$-3.2M
Net income	$-11.1M
Operating cash flow minus SBC	$-9.8M
Operating income	$-11.1M
Stock-based compensation	$2.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-0.96
Long-term assets	$250,000
Long-term liabilities	$72,000
Net cash (debt)	$-4,000
Net cash / market cap	-0.17%
Piotroski F-Score	1
Property, plant and equipment	$228,000
Shareholders' equity	$-1.6M
Tangible book value	$-1.6M
Tangible book value per share	$-0.96
Total assets	$1M
Total cash	$166,000
Total debt	$170,000
Total liabilities	$2.6M
WACC	12.36%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$778,000
Current liabilities	$2.5M
Current ratio	0.31
Net working capital	$-1.8M
Quick ratio	0.08
Working capital	$-1.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-36.98%
Dividend yield	0%
Shareholder yield	-36.98%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$10.96
1D price change	8.59%
1M price change	-65.69%
1M total return	-65.69%
1W price change	-42.8%
1W total return	-42.8%
1Y price change	-93.75%
1Y return CAGR	-93.76%
1Y total return	-93.75%
20-day SMA	$2.56
200-day SMA	$12.59
3M price change	-85.55%
3M total return	-85.55%
3Y price change	-86.36%
3Y return CAGR	-48.52%
3Y total return	-86.36%
50-day SMA	$5.07
50-day SMA vs 200-day SMA	50under200
52-week high	$25.40
52-week high date	2025-11-19
52-week low	$1.10
52-week low date	2026-11-02
6M price change	-92.47%
6M total return	-92.47%
After-hours change	2.34%
After-hours close	$1.28
After-hours price	$1.31
All-time high	$163.60
All-time high date	2022-03-21
All-time low	$1.10
All-time low date	2026-11-02
Average true range (ATR)	$0.48
Average volume	43K
Beta (1Y)	2.38
Beta (2Y)	1.11
Beta (5Y)	1.64
Change from 52-week high	-94.53%
Change from 52-week low	26.36%
Change from all-time high	-99.17%
Change from all-time low	22.73%
Change from open	8.59%
Day's gap	0%
Dollar volume	$24,016
High price	$1.39
Low price	$1.28
Monthly RSI	34.32
Open price	$1.28
Position in 52-week range	100%
Premarket change	2.34%
Premarket close	$1.28
Premarket price	$1.31
Previous close	$1.28
Price vs 150-day SMA	-87.68%
Price vs 20-day SMA	-47.33%
Price vs 200-day SMA	-89.28%
Price vs 50-day SMA	-73.35%
Relative volume	0.4
Return from IPO open	-98.59%
Return from IPO price	-78.67%
RSI	19.05
Sharpe ratio	-2.38
Sharpe ratio (3Y)	-0.13
Sortino ratio	-2.95
Sortino ratio (3Y)	-0.13
Volume	17.3K
Weekly RSI	23.66
YTD price change	-91.22%
YTD total return	-91.22%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.2M
Float percentage	67.53%
Shares change (QoQ)	0%
Shares change (YoY)	36.98%
Shares held by insiders	32.47%
Shares held by institutions	1.06%
Shares outstanding	1.8M
Short % of float	2.09%
Short % of shares	1.41%
Short ratio	1.1 days

Deeper analysis on NRSN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NRSN report

Is a complete NRSN research report available?

No complete published report is available for NeuroSense Therapeutics Ltd. (NRSN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NeuroSense Therapeutics Ltd. (NRSN)

Price

Financial snapshot

Fair-value bridge

Latest news · NRSN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NRSN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NRSN

Frequently asked questions